JP2023550998A5 - - Google Patents

Info

Publication number
JP2023550998A5
JP2023550998A5 JP2023532401A JP2023532401A JP2023550998A5 JP 2023550998 A5 JP2023550998 A5 JP 2023550998A5 JP 2023532401 A JP2023532401 A JP 2023532401A JP 2023532401 A JP2023532401 A JP 2023532401A JP 2023550998 A5 JP2023550998 A5 JP 2023550998A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023532401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550998A (ja
JP7885215B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/133514 external-priority patent/WO2022111633A1/en
Publication of JP2023550998A publication Critical patent/JP2023550998A/ja
Publication of JP2023550998A5 publication Critical patent/JP2023550998A5/ja
Application granted granted Critical
Publication of JP7885215B2 publication Critical patent/JP7885215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023532401A 2020-11-27 2021-11-26 Cldn18.2抗体及びその使用 Active JP7885215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011364033.6 2020-11-27
CN202011364033 2020-11-27
PCT/CN2021/133514 WO2022111633A1 (en) 2020-11-27 2021-11-26 Cldn18.2 antibody and use thereof

Publications (3)

Publication Number Publication Date
JP2023550998A JP2023550998A (ja) 2023-12-06
JP2023550998A5 true JP2023550998A5 (cg-RX-API-DMAC7.html) 2024-12-04
JP7885215B2 JP7885215B2 (ja) 2026-07-06

Family

ID=81712708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532401A Active JP7885215B2 (ja) 2020-11-27 2021-11-26 Cldn18.2抗体及びその使用

Country Status (8)

Country Link
US (1) US20250270313A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251652A4 (cg-RX-API-DMAC7.html)
JP (1) JP7885215B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230113578A (cg-RX-API-DMAC7.html)
CN (1) CN114560941B (cg-RX-API-DMAC7.html)
AU (1) AU2021388650A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199212A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022111633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250332197A1 (en) * 2022-03-18 2025-10-30 Sunshine Lake Pharma Co., Ltd. Claudin18.2 humanized antibody and application thereof
CN114836388A (zh) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2单克隆抗体及其制备方法和用途
CN115960229B (zh) * 2022-09-28 2024-02-09 华润生物医药有限公司 一种cldn18.2抗体及其应用
TW202440623A (zh) * 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白18﹒2之嵌合抗原受體及結合劑以及其用途
CN115873111B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用
CN116082523B (zh) * 2022-12-30 2023-10-13 邦恩泰(山东)生物医药科技集团股份有限公司 一种靶向Claudin18.2的嵌合抗原受体及其应用
CN116143924A (zh) * 2023-02-07 2023-05-23 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的人源化单克隆抗体及其应用
CN116536274B (zh) * 2023-06-20 2023-09-19 上海精翰生物科技有限公司 Claudin18.2表达稳转细胞株、制备方法及应用
CN117777307B (zh) * 2023-09-26 2024-08-20 深圳豪石生物科技有限公司 一种cldn18.2特异性嵌合t细胞受体、嵌合t细胞受体免疫细胞及其应用
WO2026020019A1 (en) * 2024-07-17 2026-01-22 Mayo Foundation For Medical Education And Research Molecules that bind to claudin polypeptides
WO2026158588A1 (zh) * 2025-01-26 2026-07-30 北京艺妙神州生物医药股份有限公司 抗Claudin18.2的抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US8840902B2 (en) * 2010-03-16 2014-09-23 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2019206207B2 (en) * 2018-01-15 2025-04-10 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
JP7401538B2 (ja) * 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗cldn18.2抗体およびその使用
MX2021007939A (es) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.

Similar Documents

Publication Publication Date Title
US12421292B2 (en) Anti-DLL3 chimeric antigen receptors and uses thereof
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
AU2019314999A1 (en) Antibody constructs for CLDN18.2 and CD3
CN112154157A (zh) 抗ror1抗体及其用途
TW201837174A (zh) 抗gprc5d抗體及包含該抗體之分子
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2019504617A5 (cg-RX-API-DMAC7.html)
JP2025508118A (ja) 新規免疫調節剤の開発および使用
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
JP2018522888A5 (cg-RX-API-DMAC7.html)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
EP4303234A1 (en) Antibody against nkp46 and application of antibody
EP4421095A1 (en) Anti-mesothelin nanobodies and use thereof
JP2016529213A5 (cg-RX-API-DMAC7.html)
JP2023547662A (ja) Cldn6及びcd3に選択的に結合するポリペプチド構築物
CN114423451A (zh) 用于多聚抗体受体靶向的材料和方法
CN120399073A (zh) 一种靶向tigit的单域抗体
WO2018179302A1 (ja) 抗ポドプラニン抗体
CN114075288B (zh) 抗pd-l2抗体
WO2023281120A1 (en) Dimeric protein complexes and uses thereof
JP2024514101A5 (cg-RX-API-DMAC7.html)
CN116554340A (zh) 新型长效化和高活性且更安全的抗体构建体
WO2023020507A1 (zh) 一种抗b7-h4抗体及其制备方法和应用
WO2024037627A1 (zh) 一种双特异性抗体及其应用